Predictors of response to TNF inhibitors in rheumatoid arthritis: Do we have new tools for personalized medicine?

Bulletin of the NYU Hospital for Joint Diseases

Volumn 70, Issue 3, 2012, Pages 187-190

  Simsek, Ismail ^a  

^a GULHANE SCHOOL OF MEDICINE   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; BIOLOGICAL MARKER; ETANERCEPT; INFLIXIMAB; INTERLEUKIN 17; INTERLEUKIN 1BETA; METHOTREXATE; RITUXIMAB; TOCILIZUMAB; TUMOR NECROSIS FACTOR INHIBITOR;

ANTIBODY BLOOD LEVEL; DISEASE ACTIVITY; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG MEGADOSE; DRUG MONITORING; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; INFUSION RELATED REACTION; LOW DRUG DOSE; PERSONALIZED MEDICINE; REVIEW; RHEUMATOID ARTHRITIS; TREATMENT OUTCOME; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

ANIMALS; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BIOLOGICAL AGENTS; BIOLOGICAL MARKERS; DRUG MONITORING; HUMANS; INDIVIDUALIZED MEDICINE; PATIENT SELECTION; PREDICTIVE VALUE OF TESTS; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84869423779     PISSN: 19369719     EISSN: 19369727     Source Type: Journal    
DOI: None     Document Type: Review

References (13)

1. Simsek I. TNF inhibitors - new and old agents for rheumatoid arthritis. Bull NYU Hosp Jt Dis. 2010; 68(3):204-10
2. Gibbons LJ, Hyrich KL. Biologic therapy for rheumatoid arthritis: clinical efficacy and predictors of response. BioDrugs. 2009;23(2):111-24
3. Marotte H, Maslinski W, Miossec P. Circulating tumour necrosis factor-alphabioactivity in rheumatoid arthritis patients treated with infliximab: link to clinical response. Arthritis Res Ther. 2005;7(1):R149-55
4. Takeuchi T, Miyasaka N, Tatsuki Y, et al. Baseline tumour necrosis factor alpha levels predict the necessity for dose escalation of infliximab therapy in patients with rheumatoid arthritis. Ann Rheum Dis. 2011 Jul;70(7):1208-15
5. Takeuchi T, Miyasaka N, Inoue K, et al. Impact of trough serum level on radiographic and clinical response to infliximab plus methotrexate in patients with rheumatoid arthritis: results from the RISING study. Mod Rheumatol. 2009;19(5):478-87
6. Kayakabe K, Kuroiwa T, Sakurai N, et al. Interleukin-1ß measurement I stimulated whole blood cultures is useful to predict response to anti-TNF therapies in rheumatoid arthritis. Rheumatology (Oxford). 2012 Sep;51(9):1639-43
7. Chen DY, Chen YM, Chen HH, et al. Increasing levels of circulating Th17 cells and interleukin-17 in rheumatoid arthritis patients with an inadequate response to anti-TNF-a therapy. Arthritis Res Ther. 2011 Jul 30;13(4):R126
8. Bartelds GM, Wijbrandts CA, Nurmohamed MT, et al. Anti-infliximab and anti-adalimumab antibodies in relation to response to adalimumab in infliximab switchers and antitumour necrosis factor naive patients: a cohort study. Ann Rheum Dis. 2010 May;69(5):817-21
9. Pascual-Salcedo D, Plasencia C, Ramiro S, et al. Influence of immunogenicity on the efficacy of long-term treatment with infliximab in rheumatoid arthritis. Rheumatology (Oxford). 2011 Aug;50(8):1445-52
10. Bartelds GM, Krieckaert CL, Nurmohamed MT, et al. Development of antidrug antibodies against adalimumab and association with disease activity and treatment failure during long-term follow-up. JAMA. 2011 Apr 13;305(14):1460-8
11. Krieckaert CL, Nurmohamed MT, Wolbink GJ. Methotrexate reduces immunogenicity in adalimumab treated rheumatoid arthritis patients in a dose dependent manner. Ann Rheum Dis. 2012 May 14. [Epub ahead of print]
12. Jamnitski A, Bartelds GM, Nurmohamed MT, et al. The presence or absence of antibodies to infliximab or adalimumab determines the outcome of switching to etanercept. Ann Rheum Dis. 2011 Feb;70(2):284-8
13. Jamnitski A, Krieckaert CL, Nurmohamed MT, et al. Patients non-responding to etanercept obtain lower etanercept concentrations compared with responding patients. Ann Rheum Dis. 2012 Jan;71(1):88-91.